Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAP-486 in Ventricular Tachyarrhythmia Induction
NCT00137332Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Nov 2005
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in ventricular tachyarrhythmia comparing GAP-486 with Placebo (2 arms). Primary endpoint: Induction of abnormally fast heart rhythm. Started Nov 2005; status: terminated.
02
Drugs
rotigaptide
03
Conditions
ventricular tachyarrhythmia
Beyond the preview
Go deeper on NCT00137332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00137332.